Experts
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Cochlear.
RELATED STOCKHEAD STORIES
Experts
Scopo’s powerplays: Investors love a result, until they don’t
Health & Biotech
The healthcare winners and losers after COVID-19, and what comes next
Health & Biotech
We’re still here: investors keen on health despite market shun
Experts
ScoPo’s health powerplays: Ramp ups and turnaround favs
Experts
ScoPo’s health powerplays: Cap raises goin’ crazy
Experts
This fund manager suggests investors need to look for businesses that will ‘always be there’
Health & Biotech
Check up: Is anyone making non-COVID-19 money these days? Actually, yes
News
This is what being on a ‘war footing’ against COVID-19 looks like
Health & Biotech
Dr Boreham’s Crucible: Why unlisted Qbiotics has a good chance of cracking the cancer market
Health & Biotech
Dr Boreham’s Crucible: The small cap biotechs trying to make a buck from coronavirus
Health & Biotech
Dr Boreham’s Crucible: Cochlear can weather the coronavirus-induced China slump
News
Will China’s post-virus stimulus help or hurt your stock?
Health & Biotech
Health: Oventus isn’t sleeping on the job because it’s making too much money
Health & Biotech
Health: Are Uscom’s sales *really* up on coronavirus?
News
Spies and corporate takeovers: what’s next for the China-Australia story?
Health & Biotech
Here’s what policymakers must do keep ASX life science companies from going overseas
Health & Biotech
